<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK</title>
	<atom:link href="http://prostatecancerinfolink.net/feed/" rel="self" type="application/rss+xml" />
	<link>http://prostatecancerinfolink.net</link>
	<description></description>
	<lastBuildDate>Thu, 17 May 2012 20:34:39 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
<cloud domain='prostatecancerinfolink.net' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<image>
		<url>http://s2.wp.com/i/buttonw-com.png</url>
		<title>THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK</title>
		<link>http://prostatecancerinfolink.net</link>
	</image>
	<atom:link rel="search" type="application/opensearchdescription+xml" href="http://prostatecancerinfolink.net/osd.xml" title="THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK" />
	<atom:link rel='hub' href='http://prostatecancerinfolink.net/?pushpress=hub'/>
		<item>
		<title>Hospital volume important to outcomes among older, sicker, Medicare patients treated by RP</title>
		<link>http://prostatecancerinfolink.net/2012/05/17/hospital-volume-important-to-outcomes-among-older-sicker-medicare-patients-treated-by-rp/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/17/hospital-volume-important-to-outcomes-among-older-sicker-medicare-patients-treated-by-rp/#comments</comments>
		<pubDate>Thu, 17 May 2012 20:34:34 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[hospital]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[surgery]]></category>
		<category><![CDATA[surgical]]></category>
		<category><![CDATA[volume]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15641</guid>
		<description><![CDATA[A media release issued by Henry Ford Health System earlier today has a distinctly misleading headline that reads as follows: &#8220;Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery.&#8221; You need to read the content of the media release with care to understand that this headline is by no means [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15641&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/17/hospital-volume-important-to-outcomes-among-older-sicker-medicare-patients-treated-by-rp/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>NICE issues new and positive draft guidance on abiraterone acetate</title>
		<link>http://prostatecancerinfolink.net/2012/05/17/nice-issues-new-and-positive-draft-guidance-on-abiraterone-acetate/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/17/nice-issues-new-and-positive-draft-guidance-on-abiraterone-acetate/#comments</comments>
		<pubDate>Thu, 17 May 2012 14:09:36 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[abiraterone]]></category>
		<category><![CDATA[access]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15637</guid>
		<description><![CDATA[According to information on the web site of the National Institute for Clinical Excellence (NICE), revised draft guidance has been issued by NICE regarding the routine use of abiraterone acetate. As we had suggested might be the case, the revision has come after abiraterone’s manufacturer, Janssen, submitted additional information to NICE that included a revised [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15637&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/17/nice-issues-new-and-positive-draft-guidance-on-abiraterone-acetate/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Abiraterone acetate may help to eliminate cancer prior to surgery in some men with high-risk, localized disease</title>
		<link>http://prostatecancerinfolink.net/2012/05/17/abiraterone-acetate-may-help-to-eliminate-cancer-prior-to-surgery-in-some-men-with-high-risk-localized-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/17/abiraterone-acetate-may-help-to-eliminate-cancer-prior-to-surgery-in-some-men-with-high-risk-localized-prostate-cancer/#comments</comments>
		<pubDate>Thu, 17 May 2012 13:52:28 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[abiraterone]]></category>
		<category><![CDATA[dutasteride]]></category>
		<category><![CDATA[enzalutamide]]></category>
		<category><![CDATA[leuprolide]]></category>
		<category><![CDATA[MDV3100]]></category>
		<category><![CDATA[neoadjuvant]]></category>
		<category><![CDATA[pre-surgical]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15631</guid>
		<description><![CDATA[According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15631&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/17/abiraterone-acetate-may-help-to-eliminate-cancer-prior-to-surgery-in-some-men-with-high-risk-localized-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Abiraterone in the UK: rumors are rife &#8230;</title>
		<link>http://prostatecancerinfolink.net/2012/05/15/abiraterone-in-the-uk-rumors-are-rife/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/15/abiraterone-in-the-uk-rumors-are-rife/#comments</comments>
		<pubDate>Tue, 15 May 2012 15:29:17 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[abiraterone]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15627</guid>
		<description><![CDATA[According to recent articles in the media, the National Institute for Clinical Excellence (NICE) will shortly issue a recommendation that abiraterone is covered for routine use in the UK among men with chemotherapy-refractory, metastatic, castration-resistant prostate cancer (mCRPC). If one believes the media reports (see The Daily Mail yesterday and The Daily Telegraph today), one [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15627&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/15/abiraterone-in-the-uk-rumors-are-rife/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Wanna learn about being a consumer/patient reviewer for the DoD PCRP?</title>
		<link>http://prostatecancerinfolink.net/2012/05/14/wanna-learn-about-being-a-consumerpatient-reviewer-for-the-dod-pcrp/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/14/wanna-learn-about-being-a-consumerpatient-reviewer-for-the-dod-pcrp/#comments</comments>
		<pubDate>Mon, 14 May 2012 23:28:25 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Prevention]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15622</guid>
		<description><![CDATA[On Wednesday this week, you can join an hour-long webcast at which Dr. Carolyn Best and a colleague from the Department of Defense Prostate Cancer Research Program (DoD PCRP) will explain what is involved and how to apply. Sign yourself up right NOW! The DoD PCRP is the single largest government-funded research program that is [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15622&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/14/wanna-learn-about-being-a-consumerpatient-reviewer-for-the-dod-pcrp/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>DNA methylation and the aggressiveness of prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2012/05/14/dna-methylation-and-the-aggressiveness-of-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/14/dna-methylation-and-the-aggressiveness-of-prostate-cancer/#comments</comments>
		<pubDate>Mon, 14 May 2012 23:08:43 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[aggressiveness]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[expression]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[methylation]]></category>
		<category><![CDATA[test]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15619</guid>
		<description><![CDATA[According to a media release from the Mayo Clinic earlier today, &#8220;Alterations to the &#8216;on-off&#8217; switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches.&#8221; The relevant research paper has &#8212; supposedly &#8211;  just been published [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15619&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/14/dna-methylation-and-the-aggressiveness-of-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>PBRT vs. IMRT &#8212; are we about to get the definitive trial?</title>
		<link>http://prostatecancerinfolink.net/2012/05/14/pbrt-vs-imrt-are-we-about-to-get-the-definitive-trial/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/14/pbrt-vs-imrt-are-we-about-to-get-the-definitive-trial/#comments</comments>
		<pubDate>Mon, 14 May 2012 13:04:21 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[IMRT]]></category>
		<category><![CDATA[PBRT]]></category>
		<category><![CDATA[photon]]></category>
		<category><![CDATA[proton]]></category>
		<category><![CDATA[radiation therapy]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15616</guid>
		<description><![CDATA[According to an article in the Boston Globe this morning, we are (supposedly and finally) going to get the study needed to try to demonstrate whether there is a real clinical benefit to proton beam radiation therapy as compared to modern, intensity-modulated radiation therapy in men with localized prostate cancer! The study is to be [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15616&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/14/pbrt-vs-imrt-are-we-about-to-get-the-definitive-trial/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Expert video-discussion on evolution in the management of late stage prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2012/05/12/expert-video-discussion-on-evolution-in-the-management-of-late-stage-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/12/expert-video-discussion-on-evolution-in-the-management-of-late-stage-prostate-cancer/#comments</comments>
		<pubDate>Sat, 12 May 2012 11:11:33 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[advanced]]></category>
		<category><![CDATA[castration-resistant]]></category>
		<category><![CDATA[mCRPC]]></category>
		<category><![CDATA[review]]></category>
		<category><![CDATA[video]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15613</guid>
		<description><![CDATA[Here is a link to a recent 20-minute video-discussion on the Medscape web site between an number of European experts on evolutions in the management of castration-resistant (and earlier forms of) prostate cancer. (You do need to sign up to be able to see material on the Medscape web site, but you can opt out [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15613&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/12/expert-video-discussion-on-evolution-in-the-management-of-late-stage-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>NICE rejects &#8220;routine&#8221; use of cabazitaxel in UK</title>
		<link>http://prostatecancerinfolink.net/2012/05/11/nice-rejects-routine-use-of-cabazitaxel-in-uk/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/11/nice-rejects-routine-use-of-cabazitaxel-in-uk/#comments</comments>
		<pubDate>Fri, 11 May 2012 18:38:24 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[cabazitaxel]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15603</guid>
		<description><![CDATA[According to a media release issued today by the National Institute for Clinical Excellence (NICE) in the UK, the institute&#8217;s advisory board will not recommend &#8220;routine&#8221; use of cabazitaxel for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). It is clear from the media release that NICE decided that the price for treatment with cabazitaxel [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15603&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/11/nice-rejects-routine-use-of-cabazitaxel-in-uk/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Updated version of book on advanced prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2012/05/11/updated-version-of-book-on-advanced-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/11/updated-version-of-book-on-advanced-prostate-cancer/#comments</comments>
		<pubDate>Fri, 11 May 2012 12:23:11 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[advanced]]></category>
		<category><![CDATA[book]]></category>
		<category><![CDATA[Malecare]]></category>
		<category><![CDATA[recurrent]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15601</guid>
		<description><![CDATA[Malecare has just issued an updated version of its free book on recurrent and advanced prostate cancer. Many people have gained great benefit from the first edition of this book, and we are sure that the new version is equally useful. However, you do have to &#8220;sign up&#8221; to be able to download the new [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15601&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/11/updated-version-of-book-on-advanced-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Can adhesion receptor blockade lower risk for metastatic prostate cancer?</title>
		<link>http://prostatecancerinfolink.net/2012/05/11/can-adhesion-receptor-blockade-lower-risk-for-metastatic-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/11/can-adhesion-receptor-blockade-lower-risk-for-metastatic-prostate-cancer/#comments</comments>
		<pubDate>Fri, 11 May 2012 11:52:48 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[adhesion]]></category>
		<category><![CDATA[blockade]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[β1 integrin]]></category>
		<category><![CDATA[metastasis]]></category>
		<category><![CDATA[Prevention]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15599</guid>
		<description><![CDATA[A group of Finnish researchers have reported the apparent existence of a series of genes that are capable of inhibiting the spread (metastasis) of prostate cancer cells &#8212; at least in the laboratory. Pellinen et al. have been able to demonstrate that the adhesive activity of prostate cancer cells, which is relatively easy to measure in a [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15599&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/11/can-adhesion-receptor-blockade-lower-risk-for-metastatic-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Outcomes research and radical prostectomy: a new review</title>
		<link>http://prostatecancerinfolink.net/2012/05/11/outcomes-research-and-radical-prostectomy-a-new-review/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/11/outcomes-research-and-radical-prostectomy-a-new-review/#comments</comments>
		<pubDate>Fri, 11 May 2012 11:33:30 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[radical prostatectomy]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[surgery]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15596</guid>
		<description><![CDATA[An article acessible for free on the Medscape web site offers an interesting summary of the state of research into the quality of outcomes during and after radical prostatectomy for the treatment of localized prostate cancer. Trinh et al. discuss the many factors that are now known to impact the probability of higher quality of [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15596&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/11/outcomes-research-and-radical-prostectomy-a-new-review/feed/</wfw:commentRss>
		<slash:comments>8</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Abiraterone acetate in chemotherapy-naïve mCRPC: data at ASCO</title>
		<link>http://prostatecancerinfolink.net/2012/05/09/abiraterone-acetate-in-chemotherapy-naive-mcrpc-data-at-asco/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/09/abiraterone-acetate-in-chemotherapy-naive-mcrpc-data-at-asco/#comments</comments>
		<pubDate>Wed, 09 May 2012 12:35:43 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15593</guid>
		<description><![CDATA[According to an article in the online issue of Oncology Business Review (see page 12 of OBR Green), the full results of the clinical trial of abiraterone acetate + prednisone vs. placebo + prednisone in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer (mCRPC) will &#8212; as previously suggested &#8212; be presented at the upcoming annual [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15593&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/09/abiraterone-acetate-in-chemotherapy-naive-mcrpc-data-at-asco/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>GTx-758 to be tested at lower doses in men with mCRPC</title>
		<link>http://prostatecancerinfolink.net/2012/05/09/15585/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/09/15585/#comments</comments>
		<pubDate>Wed, 09 May 2012 12:15:34 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Capesaris]]></category>
		<category><![CDATA[castration-resistant]]></category>
		<category><![CDATA[GTx-758]]></category>
		<category><![CDATA[mCRPC]]></category>
		<category><![CDATA[metastatic]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15585</guid>
		<description><![CDATA[According to a media release issued yesterday by GTx, Inc., the U.S. Food &#38; Drug Administration is allowing the company to proceed with a proposed, open-label, Phase II clinical trial of Capesaris® &#8212; also known as GTX-758 &#8212; in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). GTX-758 had previously been in development [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15585&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/09/15585/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Video presentation/discussion about new drugs in development</title>
		<link>http://prostatecancerinfolink.net/2012/05/08/video-presentationdiscussion-about-new-drugs-in-development/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/08/video-presentationdiscussion-about-new-drugs-in-development/#comments</comments>
		<pubDate>Tue, 08 May 2012 14:14:47 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Management]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15582</guid>
		<description><![CDATA[For those who are interested in seeing a 30-minute video of a presentation and discussion about the development of new drugs like abiraterone, MDV3100, TAK-700 (orteronel), and others, just click here. This video comes from a continuing medical education activity presented in association with the Genitourinary Cancers symposium in San Francisco back in February. Filed [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15582&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/08/video-presentationdiscussion-about-new-drugs-in-development/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
	</channel>
</rss>
